Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Drug: Doxorubicin
Drug: Bleomycin
Drug: Vinblastine
Drug: Dacarbazine
Drug: Vincristine
Radiation: Radiotherapy
Drug: Mechlorethamine
Drug: Etoposide
Drug: Prednisone
Drug: Cyclophosphamide

First Posted Date: 2003-01-27

Last Posted Date: 2023-06-29

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 854

Registration Number: NCT00003389

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 529 locations

STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00015860

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 2 locations

Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-12

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 392

Registration Number: NCT00002700

Locations: 🇸🇰
Institute of Hematology & Transfusiology, University Hospital, Bratislava, Slovakia
🇧🇪
Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium

and more 41 locations

Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 32

Registration Number: NCT00039351

Locations: 🇳🇱
Academisch Ziekenhuis Groningen, Groningen, Netherlands
🇧🇪
Ziekenhuis Network Antwerpen Middelheim, Antwerp, Belgium
🇧🇪
Centre Hospitalier Universitaire Brugmann, Brussels, Belgium

and more 14 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 400

Registration Number: NCT00003215

Locations: 🇨🇭
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
Ratisches Kantons und Regionalspital, Chur, Switzerland

and more 9 locations

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Not Applicable

Completed

Conditions: T-cell Childhood Acute Lymphoblastic Leukemia
Untreated Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: prednisone
Drug: vincristine sulfate
Drug: daunorubicin hydrochloride
Drug: asparaginase
Drug: methotrexate
Drug: cyclophosphamide
Drug: cytarabine
Drug: mercaptopurine
Drug: leucovorin calcium
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: thioguanine
Radiation: radiation therapy
Drug: pegaspargase
Other: pharmacological study
Drug: nelarabine
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT00016302

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2010-08-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 12

Registration Number: NCT00012207

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of Washington School of Medicine, Seattle, Washington, United States

S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: goserelin
Drug: mitoxantrone hydrochloride
Drug: prednisone

First Posted Date: 2003-01-27

Last Posted Date: 2022-12-30

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 983

Registration Number: NCT00004124

Locations: 🇺🇸
Cancer Care Center at Advocate Lutheran Hospital, Park Ridge, Illinois, United States
🇺🇸
Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸
Bismarck Cancer Center, Bismarck, North Dakota, United States

and more 228 locations

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Phase 3

Active, not recruiting

Conditions: Lymphoma

Interventions: Drug: cyclophosphamide
Biological: rituximab
Drug: doxorubicin
Drug: prednisone
Drug: vincristine
Radiation: tositumomab

First Posted Date: 2003-01-27

Last Posted Date: 2024-06-24

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 571

Registration Number: NCT00006721

Locations: 🇺🇸
Northside Hospital Cancer Center, Atlanta, Georgia, United States
🇺🇸
Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States
🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

and more 254 locations

S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: docetaxel
Drug: mitoxantrone
Drug: estramustine
Drug: prednisone

First Posted Date: 2003-01-27

Last Posted Date: 2014-02-25

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 770

Registration Number: NCT00004001

Locations: 🇺🇸
CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸
CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States

and more 13 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy